Nucleotide oligomerization domain polymorphism confers no risk to Guillain-Barre syndrome. Hayat S, Asad A, Hasan I, Jahan I, et al. Acta Neurol Scand 2022 Jun 2. doi: 10.1111/ane.13649.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hayat S, Asad A, Hasan I, Jahan I, et al. Nucleotide oligomerization domain polymorphism confers no risk to Guillain-Barre syndrome. Acta Neurol Scand 2022 Jun 2. doi: 10.1111/ane.13649.
PMID: 35652365